Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Wentao Feng
Institution:
Pfizer (United States)
Observed institution:
Pfizer (United States)
OpenAlex ID:
A5137095443
Efficacy and safety of tucatinib (TUC) vs placebo (PBO) combined with trastuzumab and pertuzumab (HP) as maintenance therapy for HER2+ metastatic breast cancer by stratified subgroups.
2026
·
Erika P. Hamilton
, Giuseppe Curigliano
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
1
Citation count:
H-index:
I10-index:
Year
Topic
Type
